1. Home /
  2. Biotechnology

Biotechnology

Regeneron Stock Could Fall 13% to 52-Week Lows

Regeneron Stock Could Fall 13% to 52-Week Lows

Regeneron stock is under pressure after missing on earnings and revenue expectations. Are new lows on tap?

Regeneron Declines on First-Quarter Earnings Miss

Regeneron Declines on First-Quarter Earnings Miss

The company misses big on analysts bottom-line expectations.

Allergan Expected to Earn $3.55 a Share

Allergan Expected to Earn $3.55 a Share

Allergan revenue expected to fall 3.7% to $3.5 billion.

Regeneron Pharmaceuticals Expected to Earn $5.48 a Share

Regeneron Pharmaceuticals Expected to Earn $5.48 a Share

Regeneron Pharmaceuticals revenue expected to rise 16.8% to $1.8 billion.

Dealing With Biotech Stocks That Face Setbacks

Dealing With Biotech Stocks That Face Setbacks

Knowing when to continue to fish or cut bait is something that develops over time in this space.

Gilead Sciences Is Regaining Its Shine

Gilead Sciences Is Regaining Its Shine

Revenue is stabilizing with new treatment lines, and this stock may be a soon be a buy.

Gilead Sciences Expected to Earn $1.61 a Share

Gilead Sciences Expected to Earn $1.61 a Share

Gilead Sciences revenue expected to rise 4.1% to $5.3 billion.

Amgen's First-Quarter Earnings Slump as Expenses Jump

Amgen's First-Quarter Earnings Slump as Expenses Jump

Adjusted earnings of $3.56 a share in the quarter topped analysts' expectations.

News Surrounds 3 Small Biotechs, With a Merger Claiming One

News Surrounds 3 Small Biotechs, With a Merger Claiming One

Two companies in pet pharmaceuticals plan to combine, while two other concerns are worth a look based on developments in their respective spaces.

Biogen Shares Fall After Drugmaker Meets Earnings Estimates

Biogen Shares Fall After Drugmaker Meets Earnings Estimates

The stock dips after the drugmaker beats quarterly revenue estimates and earnings meet forecasts.